Voya Investment Management LLC Takes $497,000 Position in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Voya Investment Management LLC purchased a new position in Centessa Pharmaceuticals plc (NASDAQ:CNTA) in the 4th quarter, Holdings Channel.com reports. The firm purchased 29,670 shares of the company’s stock, valued at approximately $497,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its holdings in shares of Centessa Pharmaceuticals by 68.7% in the 3rd quarter. Geode Capital Management LLC now owns 56,597 shares of the company’s stock worth $905,000 after buying an additional 23,058 shares in the last quarter. JPMorgan Chase & Co. grew its position in Centessa Pharmaceuticals by 1,969.2% in the third quarter. JPMorgan Chase & Co. now owns 135,903 shares of the company’s stock valued at $2,173,000 after acquiring an additional 129,335 shares during the period. GAMMA Investing LLC raised its stake in Centessa Pharmaceuticals by 29.1% during the fourth quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock worth $64,000 after acquiring an additional 865 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Centessa Pharmaceuticals by 39.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 18,909 shares of the company’s stock valued at $317,000 after acquiring an additional 5,316 shares during the period. Finally, Wellington Management Group LLP boosted its stake in shares of Centessa Pharmaceuticals by 14.4% in the 4th quarter. Wellington Management Group LLP now owns 115,107 shares of the company’s stock valued at $1,928,000 after purchasing an additional 14,494 shares in the last quarter. Institutional investors own 82.01% of the company’s stock.

Wall Street Analysts Forecast Growth

CNTA has been the subject of a number of recent analyst reports. Chardan Capital assumed coverage on shares of Centessa Pharmaceuticals in a research report on Thursday. They set a “buy” rating and a $30.00 target price for the company. Morgan Stanley reiterated an “overweight” rating and issued a $27.00 target price on shares of Centessa Pharmaceuticals in a research note on Friday, March 7th. Piper Sandler started coverage on Centessa Pharmaceuticals in a research report on Monday, March 31st. They set an “overweight” rating and a $38.00 price target on the stock. Guggenheim reiterated a “buy” rating and issued a $28.00 price objective on shares of Centessa Pharmaceuticals in a research report on Wednesday, March 26th. Finally, Oppenheimer started coverage on Centessa Pharmaceuticals in a report on Thursday. They set an “outperform” rating and a $6.00 target price on the stock. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat, Centessa Pharmaceuticals has an average rating of “Buy” and an average price target of $27.00.

Centessa Pharmaceuticals Trading Down 0.8 %

CNTA stock opened at $12.29 on Friday. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. Centessa Pharmaceuticals plc has a twelve month low of $7.75 and a twelve month high of $19.09. The company has a market cap of $1.64 billion, a P/E ratio of -8.03 and a beta of 1.53. The business has a fifty day moving average of $13.86 and a 200-day moving average of $15.67.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings data on Monday, March 24th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.04. As a group, equities research analysts expect that Centessa Pharmaceuticals plc will post -1.6 EPS for the current year.

Insider Activity at Centessa Pharmaceuticals

In related news, General Counsel Iqbal J. Hussain sold 6,000 shares of the company’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $16.18, for a total value of $97,080.00. Following the completion of the sale, the general counsel now owns 105,386 shares in the company, valued at approximately $1,705,145.48. This represents a 5.39 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Saurabh Saha sold 55,000 shares of the firm’s stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $15.93, for a total value of $876,150.00. Following the transaction, the chief executive officer now owns 331,017 shares in the company, valued at approximately $5,273,100.81. This trade represents a 14.25 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 171,827 shares of company stock worth $2,705,568 over the last ninety days. Company insiders own 11.59% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.